Volcano Corp (VOLC)

Has a great line of products , and as the population ages more of its products will be in demand. I see this company growing steadily , and or being bought out - either way I'm going to make money .

covered some shares on 9-20

technology wins in the end. they built a better mousetrap.

this company has some good products, and the price had beaten down so much.

with all the baby boomers, how can it be wrong to pick stocks in health care? thats right it can't.

35% yoy rev increase!

This co is working on some new products which will address ovesity, one of our major medical problems in the US--and the world.

Technology seems sound and likelihood above average that it will become used fairly widely. Buyout by Medtronic, GE or other large medical imaging or ultrasound company seems possible.

product is best in show probably a buyout canidate

almost finished forming a double bottom...

IVUS...enough said............

Volcano helps to get the blood flowing in the human heart. The company makes a variety of medical devices that diagnose and treat heart disease, including atherosclerosis. Its intravascular ultrasound (IVUS) devices give information about the condition of arteries as well as plaque and lesions. Its functional measurement (FM) products measure characteristics of blood around plaque in arteries. The company sells its products to physicians and other health care providers worldwide through a direct sales force.

During August 2006 Volcano and GE Healthcare announced the US FDA (FDA) 510(k) clearance for the integration of Volcano's IVUS capabilities onto the Innova all-digital X-ray cath-lab imaging system. This digital imaging system is designed to give interventional cardiologists and interventional radiologists a clearer view of coronary and peripheral vessel morphology in a more accessible manner than previously available.

During the last quarter of 2006, Volcano announced collaboration with three leading core labs under which the company will provide IVUS catheters free of charge for use in pivotal trials for drug-eluting stents to facilitate the use of IVUS and demonstrate its value in stent optimization. The company is in the final trial design for the CHECK study, or Carotid Histology Evaluation and Correlation to patient worKup that will be a registry of stented carotid artery patients worldwide who undergo IVUS imaging.

Currently, more than 2,500 IVUS and FM systems are installed worldwide, with approximately half of its revenues coming from outside the US. For all of fiscal 2006, Volcano reported revenues of $103.0 million, a 12% rise over revenues of $91.9 million in fiscal 2005, thanks to the IVUS disposable revenues that increased nearly 25 percent. Volcano’s management expects revenues of approximately $120.0 million in fiscal 2007, nearly a 17% increase. In view of a stable business model, strong product line, worldwide sales stretch and recent collaborations, Volcano appears as a compelling investment idea.

Ultrasound for the diagnosis and treatment of vascular and structural heart disease makes this a new tool that will be much needed globally. Plus a contract with GE and new products make this a winner

Much needed product

Very hot IPO in a very hot group (at the moment)!

contract with GE and new products make this a winner.

I think is good young company with a good product

Two words: Baby Boomers

5-star $609 million market cap on 11/26/06.
Medical equipment for diagnosis and treatment of vascular and structural heart disease.
5STARsmallCAPS picks five star stocks with the smallest market caps.